Recombinant Aptera fusca Periviscerokinin-2

What is the amino acid sequence of Periviscerokinin-2, and how might it differ in Aptera fusca compared to other cockroach species?

The sequence of Periviscerokinin-2 in Periplaneta americana has been established as Gly-Ser-Ser-Ser-Gly-Leu-Ile-Ser-Met-Pro-Arg-Val-NH2 through peptide sequence analysis and mass spectrometry . While the specific sequence in Aptera fusca has not been directly reported in the available literature, cockroach neuropeptides typically show high conservation in their C-terminal functional region.

For comparative sequence analysis, researchers should:

• Isolate perisympathetic organs from Aptera fusca specimens

• Use the isolated hyperneural muscle bioassay method as employed with P. americana

• Perform HPLC fractionation followed by mass spectrometry

• Compare the mass spectrometry profiles with known periviscerokinin sequences

• Focus particularly on the critical C-terminal PRV-amide region, which is likely conserved

How significant is the C-terminal PRVamide motif in Periviscerokinin-2 for its biological activity?

The C-terminal tripeptide sequence (PRVamide) in Periviscerokinin-2 is structurally related to the pyrokinin C-terminal tripeptide (PRLamide), explaining its cross-reactivity in certain bioassays . This region is crucial for receptor recognition and biological activity.

Methodology for investigating this significance includes:

• Site-directed mutagenesis of the recombinant peptide to create variants with substitutions in the PRVamide region

• Comparative bioassays measuring myotropic activity of native and modified peptides

• Receptor binding assays to quantify affinity differences

• Structural studies using NMR to determine conformational changes resulting from sequence modifications

What expression systems are optimal for producing biologically active recombinant Aptera fusca Periviscerokinin-2?

For recombinant production of insect neuropeptides like Periviscerokinin-2, several expression systems can be considered:

Bacterial Expression Systems:

• E. coli BL21(DE3) with pET vectors for high yield

• Challenges: Proper formation of C-terminal amidation may require additional enzymatic processing

• Protocol modifications: Use of fusion partners (SUMO, thioredoxin) to enhance solubility

Yeast Expression Systems:

• Pichia pastoris for secreted expression with natural post-translational modifications

• Advantage: Better equipped for producing amidated peptides

Insect Cell Lines:

• Sf9 or High Five™ cells with baculovirus vectors

• Most likely to properly process insect-specific post-translational modifications

• Higher cost but potentially better biological fidelity

Selection criteria should focus on preserving the critical C-terminal amidation, as this modification was confirmed to be essential for bioactivity in related periviscerokinin studies .

What purification strategy yields the highest recovery of functional recombinant Periviscerokinin-2?

A multi-step purification approach is recommended:

• Initial capture: Immobilized metal affinity chromatography (IMAC) if using His-tagged constructs

• Tag removal: Site-specific protease cleavage (TEV or PreScission protease)

• Intermediate purification: Ion-exchange chromatography

• Polishing step: Reversed-phase HPLC

Quality control measures:

• Mass spectrometry to confirm molecular weight and C-terminal amidation

• Circular dichroism to assess secondary structure

• Bioactivity testing using isolated hyperneural muscle contraction assay

• Retention time comparison between synthetic and recombinant peptides (as performed for native PVK-2)

How can researchers validate the biological activity of recombinant Aptera fusca Periviscerokinin-2?

Comprehensive validation requires multiple complementary approaches:

Myotropic Activity Assays:

• Isolated hyperneural muscle contraction assay (as used for native PVK-2 isolation)

• Dose-response curves to determine EC50 values

• Comparison with synthetic standards and native peptide if available

Receptor Binding Studies:

• Heterologous expression of putative periviscerokinin receptors

• Competitive binding assays with fluorescently labeled peptides

• GTPγS binding assays to measure receptor activation

Immunological Validation:

• Development of specific antisera against the recombinant peptide

• Immunohistochemistry to compare binding patterns with native peptide

• Western blotting to confirm recognition of native peptide

In vivo Studies:

• Injection bioassays in model insects

• Physiological response measurements (similar to those used in pyrokinin studies)

What experimental approaches can distinguish between the activities of Periviscerokinin-2 and related neuropeptides?

Differentiating the specific activities of periviscerokinin-2 from related peptides requires:

Structure-Activity Relationship Studies:

• Synthesis of chimeric peptides combining segments of periviscerokinin-2 and related neuropeptides

• Alanine scanning mutagenesis to identify critical residues

• N-terminal and C-terminal truncation series to map minimal active fragments

Receptor Selectivity Profiling:

• Parallel testing on multiple expressed neuropeptide receptors

• Calculation of selectivity indices based on relative potencies

• Antagonist studies to block specific receptor subtypes

Tissue-Specific Bioassays:

• Comparison of activities in different target tissues

• Dose-response relationships across multiple assay systems

• Temporal dynamics of response in different tissues

The critical difference between periviscerokinin-2 (PRVamide) and pyrokinins (PRLamide) can be exploited to develop selective assays, as these peptides show differential potency in pupariation acceleration activity .

How does Aptera fusca Periviscerokinin-2 compare functionally to periviscerokinins from other insect species?

Comparative analysis should examine:

Sequence Conservation Analysis:

• Alignment of periviscerokinin sequences across cockroach species and broader insect taxa

• Identification of conserved and variable regions

• Correlation of sequence variation with phylogenetic relationships

Functional Comparison:

• Cross-species bioassays testing activity in heterologous systems

• Dose-response comparisons between peptides from different species

• Investigation of species-specific receptor adaptations

Evolutionary Considerations:

• Molecular clock analysis of periviscerokinin gene family

• Assessment of selection pressures on different regions of the peptide

• Comparison with related neuropeptide families like pyrokinins and capabilities

What is the relationship between periviscerokinin gene expression patterns in Aptera fusca compared to other insects?

Investigation approaches include:

Transcriptomic Analysis:

• RNA sequencing of Aptera fusca nervous tissue to identify periviscerokinin precursor transcripts

• Comparative expression analysis across developmental stages

• Cross-species comparison of expression patterns

Cellular Localization Studies:

• In situ hybridization to map gene expression in the nervous system

• Immunohistochemistry with specific antisera

• Single-cell transcriptomics of neuronal subpopulations

Regulatory Mechanisms:

• Promoter analysis of periviscerokinin genes

• Investigation of transcription factors controlling expression

• Epigenetic regulation studies

Similar approaches have proven successful in studies of neuropeptide precursors in other polyneopteran insects .

How can mass spectrometry techniques be optimized for single-cell analysis of Periviscerokinin-2 expression in Aptera fusca neurons?

Single-cell analysis of neuropeptides requires specialized techniques:

Sample Preparation Protocol:

• Dissection of Aptera fusca abdominal ganglia under physiological conditions

• Enzymatic and mechanical dissociation to isolate individual neurons

• Identification of periviscerokinin-producing cells via preliminary immunostaining

• Direct transfer of individual cells to MALDI target plates

Mass Spectrometry Optimization:

• Matrix selection (DHB or CHCA) based on preliminary testing

• Laser intensity and pulse parameters adjusted for small sample size

• Multiple acquisition modes including reflector and MS/MS

• Internal calibration standards for accurate mass determination

Data Analysis Approach:

• Peak extraction and spectral cleaning algorithms

• Comparison with theoretical mass values

• De novo sequencing from MS/MS fragments

• Comparison with transcriptomic data

This approach has proven successful for single-cell peptide identification in other insect species, including the identification of novel tryptopyrokinin peptides in Locusta migratoria .

What methodologies can reveal the three-dimensional structure of Periviscerokinin-2 when bound to its receptor?

Structural characterization of peptide-receptor complexes requires:

NMR Spectroscopy Approach:

• Solution NMR studies of isotopically labeled peptide

• Transferred NOE experiments in the presence of receptor fragments

• Structure calculation using distance restraints from NOE data

• Molecular dynamics refinement of NMR-derived structures

X-ray Crystallography Strategy:

• Co-crystallization of receptor with periviscerokinin-2

• Stabilization of the complex using antibody fragments or nanobodies

• Synchrotron diffraction data collection

• Molecular replacement or experimental phasing for structure determination

Computational Methods:

• Homology modeling of the receptor based on related GPCRs

• Molecular docking of periviscerokinin-2 to the receptor model

• Molecular dynamics simulations to refine binding pose

• Free energy calculations to quantify binding energetics

These structural studies can identify the molecular basis for the selective recognition of the PRVamide motif compared to the related PRLamide in pyrokinins .

What bioassays can measure the physiological effects of recombinant Aptera fusca Periviscerokinin-2 in vivo?

Several bioassay approaches can be employed:

Myotropic Activity Measurement:

• Isolated gut contraction assay

• Video-based quantification of contraction frequency and amplitude

• Dose-response analysis from picomolar to micromolar concentrations

• Comparison with known myostimulatory peptides

Diuretic/Anti-diuretic Effects:

• Modified Ramsay assay for measuring fluid secretion rate

• Ion flux measurements in Malpighian tubules

• Measurement of cyclic nucleotide levels in target tissues

Neurophysiological Recordings:

• Intracellular recordings from identified neurons

• Calcium imaging in relevant ganglia

• Extracellular recordings from nerves innervating target organs

These assays should be calibrated using synthetic periviscerokinin-2 with confirmed structure to establish reference activity levels.

How can researchers investigate potential cross-reactivity between Periviscerokinin-2 and other neuropeptide receptors?

Systematic analysis of receptor interactions requires:

Receptor Expression Profile:

• Heterologous expression of all known neuropeptide receptors from Aptera fusca

• Screening with labeled periviscerokinin-2 at multiple concentrations

• Competition assays with unlabeled peptides

• Calculation of binding affinities and selectivity indices

Second Messenger Assays:

• Calcium mobilization assays (FLIPR or aequorin-based)

• cAMP accumulation measurements

• ERK phosphorylation detection

• β-arrestin recruitment assays

Bioinformatic Prediction:

• Sequence-based clustering of neuropeptide receptors

• Structural modeling of binding pockets

• Virtual screening of periviscerokinin-2 against receptor models

• Identification of conserved binding determinants

This type of comprehensive profiling can identify unexpected interactions, as observed with the cross-reactivity between periviscerokinin-2 and pyrokinin assays due to the similar C-terminal sequences .